35.5% decline in one month for Nanobiotix share, which gains 2%
The Paris-based biotech company specializing in nanomedicine oncology is recovering ground in mid-morning trading, within a rising SBF 120 index. This rebound occurs after a particularly severe monthly sequence that has swept away the main technical levels of the security.
A rebound that only makes up a tiny fraction of a 35% monthly decline
Nanobiotix shares gain 2.14% to €20.96, compared to €20.52 the previous day, while the SBF 120 advances 0.98%. The security ranks 26th in the index for the session, among the strongest gains of the day. This rebound remains modest compared to past performances: the security still loses 17.48% over one week and 35.51% over one month, so that today's gain only compensates for a fraction of the decline.
The price rests on the support level at €20.52, which is the previous day's closing level, while the RSI at 21 reflects a marked oversold configuration. The security remains well below its moving averages: the gap is 23.89% with the 20-day MA, and 27.10% with the 200-day MA.
Financing secured until 2029, published on September 24 with first-half results
At the publication of the operational and financial update for H1 2026 on September 24, the company indicated it had €110.9 million in cash, which should finance its operations until 2029. It estimates it can meet its financial obligations for at least the next twelve months, a substantial point regarding the company's ability to continue its operations. This data is included in the half-yearly results already detailed.
The biotech is listed both in Paris and on Nasdaq, where the NBTX ADS represents one ordinary share: the two lines most often move in the same direction on the same day. The Paris share is eligible for the PEA, the Nasdaq ADS is not. The next technical level to watch is the support at €20.52.
